GERN

Geron Corporation (GERN) | Rumor.io

Geron

GERN

Attention (50-day avg)0%

Attention rank (50-day avg)#2,036

Bullish sentiment (50-day avg)95%

Price to earnings ratio-9.58

Market capitalization803.1M

Earnings per share-0.11

Dividend yield (TTM)—

Revenue (annual)183.9M

Net income (annual)-83.5M

Social

What share of all stock conversation is about GERN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Sep 2

Geron Corporation's stock ($GERN) has experienced a significant increase, with some users expressing surprise and optimism about the stock's performance.
Analysts and investors are discussing the potential for Geron's stock to reach $1.60, with some users referencing the need for the stock to hold at a specific price to maintain momentum.
There is ongoing discussion about Geron's product, imetelstat, and its potential impact on the company's stock, with some users referencing the mention of imetelstat in a recent news article.

Generated by AI

Sentiment

Of the messages about GERN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	100% +4.35	93.83% -4.02	87.39% +8.48
Bearish	0% 0	0% -4.35	6.17% +4.02	12.61% -8.48

Bullish· Aug 5

The company has reported incremental turnaround with Q2 revenue growth of 11% and operational runway for the foreseeable future, suggesting a strong foundation for future growth.
The asset's cash flow and profitability are becoming more realistic near-term goals, with operating expenses staying at the same level and no diluting capital injection on the horizon.
The company's investments in research and development, particularly in chemistry, manufacturing, and controls, are expected to drive down unit production costs and set up Rytelo for stronger long-term gross margins as volume grows.

Bearish· Feb 25

$GERN's Q4 earnings and revenue missed expectations, with a net loss of $48M and a focus on RYTELO adoption in LR-MDS.
The company's stock price dropped 11.54% on the news, with some analysts attributing the decline to a lack of guidance and messaging from management.
The stock's short-term performance is uncertain, with some predicting a "stuck" equilibrium and others warning of a potential breakdown if support levels are breached.

Generated by AI

Topics

Of the messages about GERN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	14.75%	56.08%
Earnings	—	0%	4.92%	4.87%
Technical Analysis	—	0%	4.92%	18%
Macro	—	0%	37.7%	8.58%
Analysts	—	0%	37.7%	10.53%
Controversies	—	0%	0%	1.95%

Earnings· Nov 1

Geron Corporation ($GERN) reports FQ3 earnings of -3c EPS and $0.17M Revs.
$GERN beats the Estimize EPS Consensus by 2c, but misses the Estimize Revenue Consensus by $0.12M.
Options are priced for a bigger-than-average earnings move for $GERN, indicating high volatility ahead of the report.

Analysts· Jun 10

Barclays initiated coverage on Geron (GERN) at Overweight rating with a $9 price target, citing the FDA's approval of imetelstat for myelodysplastic syndromes.
Stifel maintained a Buy rating for Geron (GERN) and raised its price target to $7, following the FDA's approval of imetelstat.
Goldman Sachs increased its peak sales estimates for Geron (GERN) to $1.2 billion, citing the FDA approval label for Rytelo (imetelstat) as a positive development.

Announcements· Aug 6

Geron Corporation has appointed Harout Semerjian as President and CEO, effective August 7, 2025, with a compensation package that includes a base salary of $800,000 and stock options for 11 million shares.
The company reported a 24% increase in net product revenue, reaching $49.0 million for Q2 2025, while also nearing full enrollment in its Phase 3 clinical trial for imetelstat.
Geron's Q2 2025 earnings showed a net loss of -$16.4m, EPS -$0.02, revenue of $49m, and cash of $432.6m, with RYTELO sales increasing by 24% QoQ.

Controversies· Sep 27

Geron Corporation's ($GERN) Imetelstat collaboration with Janssen was discontinued, with Janssen owing $GERN a billion for the partnership.
The termination of the collaboration led to a significant decline in $GERN's stock price, with shares falling 70% at one point.
$GERN is under investigation for potential violation of federal securities law, and lawsuits are expected to follow the termination of the collaboration.

Technical Analysis· Jun 18

$GERN is setting up for another possible run at $7, with a 7th possible repeat pattern setup.
The stock is recovering from a previous entry at the top, with the author waiting for a clear signal, volume, price, and momentum to re-enter.
Key levels for $GERN include breaking over $2.20 for more uptrend, $2.37 for confirmation, and $2.65 for a full breakout.

Generated by AI

Community

Of the messages about GERN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	50%	67.27%	67.77%
Newcomers	0%	50%	32.73%	32.23%

Regulars· Sep 2

The price of $GERN is experiencing a significant surge, with several posts expressing optimism and a desire to see the stock break through $1.65 and potentially reach $2.
The regulars are discussing imetelstat, Geron's lead product candidate, and its potential implications, including its mention in a recent study and its comparison to other treatments.
There is concern about the lack of notable news driving the recent price spike, and one post suggests that the stock's movement is typically followed by increased volume and price movement around earnings announcements.

Newcomers· Feb 25

Geron's Q4 revenue hit $48M, with $183.6M in RYTELO sales for 2025, and the company is guiding for growth in 2026 despite cutting staff by a third.
The company's Q4 results fell short of expectations, with a net loss of $31.1M and a net loss narrowing to $85.8M for the full year.
Geron's stock price dropped 10% pre-market, but the company expects 2026 RYTELO net product revenue to be a key focus, with upcoming catalysts including an interim analysis of IMpactMF Phase III in H2 2026.

Generated by AI

News

Analysts Offer Insights on NA Companies: Geron (GERN) and Fair Isaac (FICO)

Detailed price information for Fair Isaac and Company (FICO-N) from The Globe and Mail including charting and trades.

7d agoThe Globe and Mail

Geron Eyes High End of 2026 RYTELO Revenue Guidance as Community Adoption Expands

Geron (NASDAQ:GERN) executives said the company remains on track to generate 2026 RYTELO net revenue of $220 million to $240 million, with Chief Executive Officer Harout Semerjian saying the company now expects results toward the midpoint to high end of that range, or approximately $230 million to $

13d agoYahoo Finance

Geron Sees RYTELO Revenue Near High End of 2026 Guidance as Community Use Expands

Geron (NASDAQ:GERN) said it expects full-year net revenue from RYTELO to land in the mid-to-high end of its previously stated range, or approximately $230 million to $240 million, as the company continues to expand use of the telomerase inhibitor in lower-risk myelodysplastic syndromes, or MDS. Dur

16d agoYahoo Finance

Also Discussed

Investors talking about GERN also mention

#	Name	Attention
1	Verastem Inc.VSTM	0%0
2	Incyte Corp.INCY	0%new
3	Exelixis Inc.EXEL	0%-0.03
4	Daxor CorporationDXR	0%0
5	IGC Pharma Inc.IGC	0.01%+0
6	CorMedix Inc.CRMD	0%+0
7	Amarin Corporation plc ADRAMRN	0%+0
8	DRRX - DURECT Corporation	——
9	Galectin Therapeutics Inc.GALT	0.01%+0.01
10	AFMD - Affimed N.V.	——

Geron Corporation

Healthcare
Biotechnology

Geron Corporation is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for blood cancers and related hematologic disorders. Its lead product is RYTELO (imetelstat), a telomerase inhibitor used in the treatment of adult patients with lower-risk myelodysplastic syndromes who have transfusion-dependent anemia. The company’s work centers on oncology programs that target abnormal blood-forming cells, with an emphasis on myeloid malignancies and other disorders of the bone marrow and blood. Geron Corporation serves the specialized hematology-oncology market by advancing targeted treatment options for patients with limited alternatives, supporting use across clinical practice, specialty care settings, and disease-focused treatment centers. Headquartered in Foster City, California, Geron Corporation is positioned as a focused biotechnology company built around telomerase inhibition and commercial therapy development.

Website

Location

919 East Hillsdale Boulevard

Foster City, CA, 94404

United States

Social

What share of all stock conversation is about GERN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Sep 2

Geron Corporation's stock ($GERN) has experienced a significant increase, with some users expressing surprise and optimism about the stock's performance.
Analysts and investors are discussing the potential for Geron's stock to reach $1.60, with some users referencing the need for the stock to hold at a specific price to maintain momentum.
There is ongoing discussion about Geron's product, imetelstat, and its potential impact on the company's stock, with some users referencing the mention of imetelstat in a recent news article.

Generated by AI

Sentiment

Of the messages about GERN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	100% +4.35	93.83% -4.02	87.39% +8.48
Bearish	0% 0	0% -4.35	6.17% +4.02	12.61% -8.48

Bullish· Aug 5

The company has reported incremental turnaround with Q2 revenue growth of 11% and operational runway for the foreseeable future, suggesting a strong foundation for future growth.
The asset's cash flow and profitability are becoming more realistic near-term goals, with operating expenses staying at the same level and no diluting capital injection on the horizon.
The company's investments in research and development, particularly in chemistry, manufacturing, and controls, are expected to drive down unit production costs and set up Rytelo for stronger long-term gross margins as volume grows.

Bearish· Feb 25

$GERN's Q4 earnings and revenue missed expectations, with a net loss of $48M and a focus on RYTELO adoption in LR-MDS.
The company's stock price dropped 11.54% on the news, with some analysts attributing the decline to a lack of guidance and messaging from management.
The stock's short-term performance is uncertain, with some predicting a "stuck" equilibrium and others warning of a potential breakdown if support levels are breached.

Generated by AI

Topics

Of the messages about GERN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	14.75%	56.08%
Earnings	—	0%	4.92%	4.87%
Technical Analysis	—	0%	4.92%	18%
Macro	—	0%	37.7%	8.58%
Analysts	—	0%	37.7%	10.53%
Controversies	—	0%	0%	1.95%

Earnings· Nov 1

Geron Corporation ($GERN) reports FQ3 earnings of -3c EPS and $0.17M Revs.
$GERN beats the Estimize EPS Consensus by 2c, but misses the Estimize Revenue Consensus by $0.12M.
Options are priced for a bigger-than-average earnings move for $GERN, indicating high volatility ahead of the report.

Analysts· Jun 10

Barclays initiated coverage on Geron (GERN) at Overweight rating with a $9 price target, citing the FDA's approval of imetelstat for myelodysplastic syndromes.
Stifel maintained a Buy rating for Geron (GERN) and raised its price target to $7, following the FDA's approval of imetelstat.
Goldman Sachs increased its peak sales estimates for Geron (GERN) to $1.2 billion, citing the FDA approval label for Rytelo (imetelstat) as a positive development.

Announcements· Aug 6

Geron Corporation has appointed Harout Semerjian as President and CEO, effective August 7, 2025, with a compensation package that includes a base salary of $800,000 and stock options for 11 million shares.
The company reported a 24% increase in net product revenue, reaching $49.0 million for Q2 2025, while also nearing full enrollment in its Phase 3 clinical trial for imetelstat.
Geron's Q2 2025 earnings showed a net loss of -$16.4m, EPS -$0.02, revenue of $49m, and cash of $432.6m, with RYTELO sales increasing by 24% QoQ.

Controversies· Sep 27

Geron Corporation's ($GERN) Imetelstat collaboration with Janssen was discontinued, with Janssen owing $GERN a billion for the partnership.
The termination of the collaboration led to a significant decline in $GERN's stock price, with shares falling 70% at one point.
$GERN is under investigation for potential violation of federal securities law, and lawsuits are expected to follow the termination of the collaboration.

Technical Analysis· Jun 18

$GERN is setting up for another possible run at $7, with a 7th possible repeat pattern setup.
The stock is recovering from a previous entry at the top, with the author waiting for a clear signal, volume, price, and momentum to re-enter.
Key levels for $GERN include breaking over $2.20 for more uptrend, $2.37 for confirmation, and $2.65 for a full breakout.

Generated by AI

Community

Of the messages about GERN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	50%	67.27%	67.77%
Newcomers	0%	50%	32.73%	32.23%

Regulars· Sep 2

The price of $GERN is experiencing a significant surge, with several posts expressing optimism and a desire to see the stock break through $1.65 and potentially reach $2.
The regulars are discussing imetelstat, Geron's lead product candidate, and its potential implications, including its mention in a recent study and its comparison to other treatments.
There is concern about the lack of notable news driving the recent price spike, and one post suggests that the stock's movement is typically followed by increased volume and price movement around earnings announcements.

Newcomers· Feb 25

Geron's Q4 revenue hit $48M, with $183.6M in RYTELO sales for 2025, and the company is guiding for growth in 2026 despite cutting staff by a third.
The company's Q4 results fell short of expectations, with a net loss of $31.1M and a net loss narrowing to $85.8M for the full year.
Geron's stock price dropped 10% pre-market, but the company expects 2026 RYTELO net product revenue to be a key focus, with upcoming catalysts including an interim analysis of IMpactMF Phase III in H2 2026.

Generated by AI

Geron

Social

Sep 2

Bullish· Aug 5

Bearish· Feb 25

Earnings· Nov 1

Analysts· Jun 10

Announcements· Aug 6

Controversies· Sep 27

Technical Analysis· Jun 18

Regulars· Sep 2

Newcomers· Feb 25

Analysts Offer Insights on NA Companies: Geron (GERN) and Fair Isaac (FICO)

Geron Eyes High End of 2026 RYTELO Revenue Guidance as Community Adoption Expands

Geron Sees RYTELO Revenue Near High End of 2026 Guidance as Community Use Expands

Geron at cantor healthcare conference: RYTELO growth, profit path

Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?

Kuehn Law Encourages Investors of Geron Corporation to Contact Law Firm

Also Discussed

Geron Corporation

Company Information

Location

Analysts Offer Insights on NA Companies: Geron (GERN) and Fair Isaac (FICO)

Geron Eyes High End of 2026 RYTELO Revenue Guidance as Community Adoption Expands

Geron Sees RYTELO Revenue Near High End of 2026 Guidance as Community Use Expands

Geron at cantor healthcare conference: RYTELO growth, profit path

Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?

Kuehn Law Encourages Investors of Geron Corporation to Contact Law Firm

Also Discussed

Social

Sep 2

Bullish· Aug 5

Bearish· Feb 25

Earnings· Nov 1

Analysts· Jun 10

Announcements· Aug 6

Controversies· Sep 27

Technical Analysis· Jun 18

Regulars· Sep 2

Newcomers· Feb 25